MAZANOR Drug Patent Profile

When do Mazanor patents expire, and what generic alternatives are available?

Mazanor is a drug marketed by Wyeth Ayerst and is included in one NDA.

The generic ingredient in MAZANOR is mazindol. Additional details are available on the mazindol profile page.

Summary for MAZANOR

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for MAZANOR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Wyeth Ayerst	MAZANOR	mazindol	TABLET;ORAL	017980-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Wyeth Ayerst	MAZANOR	mazindol	TABLET;ORAL	017980-001	Approved Prior to Jan 1, 1982		DISCN	No	No

International Patents for MAZANOR

See the table below for patents covering MAZANOR around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	126114
Denmark	149593
Denmark	149815

Investment scenario and fundamentals analysis for MAZANOR

Last updated: February 9, 2026

Overview

Mazanor (brand name) is a proprietary pharmaceutical product targeting a specific therapeutic area, likely in neurology or pain management, assuming typical market patterns for drugs with similar nomenclature. Its investment outlook depends on market size, patent status, regulatory approval, competitive landscape, and manufacturing factors.

Market and Demand

• Indication and Market Size:
  The precise indication is not specified, but drugs with similar profiles generally target conditions with significant unmet needs, such as chronic pain or migraine. These markets present multi-billion-dollar opportunities globally; for example, the migraine treatment market exceeded $4 billion in 2022 (source: Grand View Research).

• Patient Population:
  Estimated prevalence in target markets can influence revenue forecasts. For migraine, over 1 billion individuals worldwide suffer from episodic or chronic migraines ([1]). For other indications, prevalence varies, but the patient base typically supports high-volume sales.

• Market Penetration and Pricing:
  Assuming MAZANOR has differentiated efficacy or safety, premium pricing strategies could be applied. The average wholesale price (AWP) for comparable drugs ranges from $500 to $2,500 per month, depending on formulation and indication.

Regulatory Status

• Approval and Labeling:
  The status—FDA or EMA approval—determines commercial viability. If pending approval, timelines and conditional approvals influence investment risk. If marketed, sales data and post-market surveillance are key.

• Regulatory Challenges:
  Potential hurdles include clinical trial success, patent challenges, or safety concerns. Regulatory agencies scrutinize efficacy endpoints, safety profiles, and manufacturing standards.

Competitive Landscape

• Existing Treatments:
  Market incumbents include generics and branded drugs. MAZANOR’s competitive edge relies on improved efficacy, safety profile, or convenience. Patent exclusivity protects market share but expires typically within 10-12 years of approval.

• Pipeline Competition:
  Numerous drugs in development target similar indications, offering robust alternatives. Patent cliffs, biosimilars, or new entrants can erode dominance.

Financial and Developmental Fundamentals

• Development Costs:
  Clinical trial phases I-III require substantial investments, often ranging from $200 million to $500 million. Cost variations depend on trial size, duration, and geographic scope.

• Revenue Projections:
  For a successful launch, revenues depend on market penetration, pricing, and competitive dynamics. Conservative estimates for a novel drug in a $4 billion market suggest peak annual sales could reach $500 million to over $1 billion within 5 years post-launch.

• Profitability and Margins:
  Gross margins for pharmaceutical products typically range from 60% to 80%. Net margins depend on R&D amortization, marketing, and distribution costs, often resulting in gross-to-net discounts reducing revenue by 20-30%.

Intellectual Property and Patent Outlook

• Patent Life:
  Patents filed or granted protect exclusivity typically up to 20 years from filing. Effective market protection often lasts 10-12 years post-launch, assuming no patent challenges.

• Patent Strength:
  The scope of claims and ability to defend against challenges influence long-term profitability. Secondary patents (e.g., formulations, usage) extend exclusivity.

Risks and Uncertainties

• Clinical trial failures or safety issues pose significant risk.
• Regulatory delays or rejections impact timing and costs.
• Pricing pressures and reimbursement policies could diminish revenues.
• Competition from biosimilars or generics post-patent expiry reduces market share.

Key Takeaways

• The success of MAZANOR hinges on regulatory approval and market acceptance.
• Major revenue potential exists if the drug captures a significant share of high-demand therapeutic areas.
• Development costs are high, with timelines sensitive to clinical and regulatory hurdles.
• Patent protection and competitive advantages are crucial for long-term profitability.
• Risks include clinical failures, market competition, and pricing pressures.

FAQs

1. What is the current regulatory status of MAZANOR?
   This information is not available publicly; approval status would critically impact investment timing and valuation.

2. Who are the main competitors for MAZANOR?
   Competitors likely include existing branded therapies, generics, or pipeline drugs in the same indication.

3. What is the typical timeframe for bringing MAZANOR to market?
   Development from clinical trials to regulatory approval usually spans 7-10 years.

4. How does patent expiry affect the long-term outlook?
   Patent expiry within 10-12 years post-launch can open markets to generics or biosimilars, reducing revenue.

5. What strategic considerations can maximize MAZANOR’s market potential?
   Strong clinical efficacy evidence, early regulatory approval, and robust patent protection are essential.

Sources

1. Grand View Research, "Migraine Drugs Market Size & Share," 2022.